Test Price
3,800 AED✅ Home Collection Available
Pancreatic Mutation Panel in UAE | 3800 AED | DHA Licensed Genetic Diagnostics
Executive Summary & Core Metrics
Executive Summary
The Pancreatic Mutation Panel is a next‑generation sequencing (NGS) test that screens for germline mutations associated with hereditary pancreatic cancer susceptibility, including genes such as BRCA2, PALB2, and ATM. Offered exclusively by DNA Labs UAE with DHA Facility License No. 1143, this panel delivers 99.9% analytical sensitivity for point mutations and copy number variants through ISO‑accredited NGS processing.
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO‑accredited NGS processing on Illumina NovaSeq platform.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic post‑test clinical interpretation by a DHA‑licensed Consultant Medical Genetics.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The Pancreatic Mutation Panel employs targeted capture next‑generation sequencing (NGS) to analyze a curated set of genes implicated in hereditary pancreatic cancer. The bioinformatics pipeline detects single nucleotide variants, small insertions/deletions, and copy number alterations with high confidence. This comprehensive approach replaces the need for sequential single‑gene Sanger testing, providing a complete risk profile from a single blood draw.
| Feature | Our Test (NGS Panel) | Closest Alternative (Single‑Gene Sanger) |
|---|---|---|
| Precision | 99.9% analytical sensitivity for point mutations & CNVs | Limited to one gene; misses multi‑gene interactions |
| Method | Illumina NovaSeq NGS with bioinformatics pipeline | Capillary Sanger sequencing |
| Speed | 4–6 weeks (comprehensive multi‑gene analysis) | 6–8 weeks per gene |
Physician Insight & Safety Protocols
“Genetic testing is a powerful step toward personalised prevention. A positive result does not mean a cancer diagnosis but an opportunity for enhanced surveillance and risk reduction. I urge you to discuss every finding with your doctor before taking any clinical action.”
– Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory: Medication & Clinical Management
Clinical Safety Advisory
Do not discontinue prescribed medication or alter treatment plans without consulting your doctor. This genetic test investigates hereditary risk for pancreatic cancer and does not modify ongoing treatment regimens. All findings must be interpreted in conjunction with a complete clinical evaluation by a qualified physician.
Exclusion Criteria & Emergency Red Flags
- Not suitable for individuals unable to provide valid informed consent (or minors without court‑approved guardian consent under applicable UAE medical liability regulations).
- Postpone collection during active febrile illness or recent blood transfusion (within 2 weeks).
- Seek emergency care immediately if you develop severe abdominal pain, jaundice, or unexplained weight loss – do not wait for genetic results.
Patient FAQ & Clinical Guidance
1. How long does the Pancreatic Mutation Panel take and what does it report?
Results are typically ready in 4 to 6 weeks. The comprehensive report lists all detected pathogenic and likely pathogenic variants, benign variants, and variants of uncertain significance (VUS) along with clinical interpretations and management recommendations based on current guidelines.
2. Do I need a prescription to undergo this test?
Yes, a valid prescription from a licensed physician is required for this genetic test. In cases of pre‑surgical evaluation, pregnancy, or international travel, exceptions may be considered upon review by the referring clinician. Direct patient inquiries can be directed to our care coordination team.
3. What should I do if the result is positive for a genetic mutation?
A positive result indicates an increased genetic susceptibility to pancreatic cancer, not a diagnosis of cancer. You should schedule a consultation with an oncologist or genetic counsellor to develop a personalised surveillance and risk management plan. Enhanced screening and preventive strategies may be recommended based on the specific gene involved and family history.
4. Can this test be performed during pregnancy or while breastfeeding?
Genetic testing for hereditary cancer susceptibility can be performed during pregnancy and lactation as it requires only a peripheral blood draw and poses no risk to the foetus or infant. However, we recommend discussing timing with your obstetrician and genetic counsellor to coordinate appropriate care.
5. Will my insurance cover the cost of this test?
Coverage varies by insurance provider and policy. Our team can verify your insurance eligibility and provide a cost estimate prior to testing. For direct billing inquiries, contact us via WhatsApp at +971 54 548 8731 with your insurance details.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Data Protection
This genetic testing service strictly adheres to Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) for all patient data processing, storage, and transfer. Clinical data handling complies with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, ensuring secure electronic health records and telemedicine practices. All patient consent and safety protocols are governed by Federal Decree‑Law No. 4 of 2016 on Medical Liability. DNA Labs UAE processing facility holds ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) and operates under DHA Facility License No. 1143.
Clinical & Logistical Metadata
| Test Name | Pancreatic Mutation Panel (NGS) |
| Price (AED) | 3,800 AED |
| Turnaround Time | 4–6 weeks |
| Sample Type / Matrix | Peripheral Whole Blood |
| Methodology Used | Next‑Generation Sequencing (NGS) on Illumina NovaSeq Platform with targeted capture & bioinformatics analysis |
| ICD-10-CM Code | Z15.03 (Genetic susceptibility to malignant neoplasm of pancreas) |
| LOINC Code | 89768-8 (Comprehensive hereditary cancer panel) |
| DHA Facility License & Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians